Black Diamond Therapeutics Inc Stock
Black Diamond Therapeutics Inc Stock price
Key metrics
| Market capitalization | $123.92m |
| Enterprise Value | $34.24m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 1.27 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-81.36m |
| Cash position | $112.68m |
| EPS (TTM) EPS | $-1.36 |
| P/E forward | negative |
Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Black Diamond Therapeutics Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Black Diamond Therapeutics Inc forecast:
Analyst Opinions
7 Analysts have issued a Black Diamond Therapeutics Inc forecast:
Financial data from Black Diamond Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.34 -0.34 |
90%
90%
|
|
| EBITDA | -81 -81 |
4%
4%
|
EBIT (Operating Income) EBIT | -81 -81 |
7%
7%
|
| Net Profit | -73 -73 |
13%
13%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Black Diamond Therapeutics Inc Stock News
Company Profile
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
| Head office | United States |
| CEO | Mark Velleca |
| Employees | 54 |
| Founded | 2014 |
| Website | www.blackdiamondtherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
